Collegium Pharmaceutical Inc (NASDAQ:COLL) has earned a consensus rating of “Buy” from the ten ratings firms that are presently covering the firm, MarketBeat.com reports. Three analysts have rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $30.60.
COLL has been the subject of a number of research analyst reports. Cantor Fitzgerald reaffirmed a “buy” rating and set a $35.00 price target on shares of Collegium Pharmaceutical in a research report on Monday, January 7th. ValuEngine downgraded Collegium Pharmaceutical from a “hold” rating to a “sell” rating in a research report on Tuesday, February 12th. Zacks Investment Research downgraded Collegium Pharmaceutical from a “buy” rating to a “hold” rating in a research report on Tuesday, March 26th. BidaskClub downgraded Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research report on Saturday, February 9th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $33.00 price target (down from $35.00) on shares of Collegium Pharmaceutical in a research report on Wednesday, January 16th.
In other Collegium Pharmaceutical news, Director Michael Thomas Heffernan sold 25,000 shares of the firm’s stock in a transaction on Monday, April 15th. The stock was sold at an average price of $15.09, for a total value of $377,250.00. Following the completion of the sale, the director now directly owns 207,170 shares of the company’s stock, valued at $3,126,195.30. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders sold 75,000 shares of company stock valued at $1,176,750 over the last three months. Company insiders own 8.08% of the company’s stock.
Shares of COLL traded down $0.09 on Thursday, reaching $13.52. 425,250 shares of the company’s stock traded hands, compared to its average volume of 404,032. The company has a quick ratio of 1.21, a current ratio of 1.26 and a debt-to-equity ratio of 0.11. Collegium Pharmaceutical has a 52-week low of $13.10 and a 52-week high of $28.91.
Collegium Pharmaceutical (NASDAQ:COLL) last issued its quarterly earnings results on Wednesday, February 27th. The specialty pharmaceutical company reported $0.27 EPS for the quarter, beating the Zacks’ consensus estimate of ($0.38) by $0.65. The company had revenue of $73.40 million during the quarter, compared to the consensus estimate of $72.71 million. Collegium Pharmaceutical had a negative return on equity of 41.12% and a negative net margin of 13.95%. Collegium Pharmaceutical’s revenue was up 579.6% on a year-over-year basis. During the same period last year, the business posted ($0.54) earnings per share. Research analysts predict that Collegium Pharmaceutical will post -0.31 earnings per share for the current year.
About Collegium Pharmaceutical
Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, develops and commercializes various products for patients suffering from pain. It provides DETERx platform technology that is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods of abuse and misuse, including chewing, crushing, heating, and injecting.
Read More: Golden Cross
Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.